PI3k inhibitor

FDA's ODAC votes unanimously that future PI3K inhibitors should include randomized data for blood cancers
Endpoints
Thu, 04/21/22 - 11:32 pm
FDA
PI3k inhibitor
FDA’s Cancer Advisory Committee to Evaluate Safety of PI3K inhibitors
BioSpace
Wed, 04/20/22 - 11:19 pm
FDA
regulatory
cancer
PI3k inhibitor
FDA Concerns Over PI3K Inhibitors Snag MEI Pharma, Kyowa Kirin
BioSpace
Fri, 03/25/22 - 10:35 am
MEI Pharma
Kyowa Kirin
FDA
zandelisib
PI3k inhibitor
FDA's oncology adcomm to review PI3K inhibitors in blood cancers in April
Endpoints
Wed, 03/9/22 - 10:59 am
FDA
regulatory
blood cancers
PI3k inhibitor
Micro-cap Mei Pharma lands $100M upfront on beleaguered PI3K pathway
Endpoints
Tue, 04/14/20 - 10:03 am
MEI Pharma
cancer
PI3k inhibitor
Novartis’ PI3K drug hits goal in phase 3 breast cancer trial, laying groundwork for talks with regulators
Fierce Biotech
Thu, 08/23/18 - 10:19 am
Novartis
PI3k inhibitor
BYL719
clinical trials
breast cancer
Can Gilead break into cancer? With Zydelig approval, it gets its chance
Fierce Pharma
Fri, 07/25/14 - 09:16 am
Gilead Sciences
Zydelig
PI3k inhibitor
Roche